Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment-Reference-Cited by-同舟云学术

Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment

Published:2012-07-29 Issue:9 Volume:304 Page:707-717
ISSN:0340-3696
Container-title:Archives of Dermatological Research
language:en
Short-container-title:Arch Dermatol Res

Author:

Lamel Sonia A.,Myer Kaley A.,Younes Naji,Zhou James A.,Maibach Hilda,Maibach Howard I.

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00403-012-1266-9.pdf

Reference69 articles.

1. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Al Kavanaugh (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150–1157

2. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227–1236

3. Asahina A, Nakagawa H, Etoh T, Ohtsuki M (2010) Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study. J Dermatol 37:299–310

4. Beecher HK (1955) The powerful placebo. J Am Med Assoc 159:1602–1606

5. Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, Herdman M, Firth P, Hotchkiss K (2006) A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: psoriasis Area and Severity Index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment. Br J Dermatol 155:707–713

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis;Dermatology;2020-09-07

2. Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis;Journal of Comparative Effectiveness Research;2020-07

3. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response;PLOS ONE;2019-08-14

4. Granulocyte–macrophage colony‐stimulating factor ( GM ‐ CSF ) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐ GM ‐ CSF monoclonal antibody;British Journal of Dermatology;2019-06

5. Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement;Journal of the European Academy of Dermatology and Venereology;2019-03-12